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Side effects of cyclosporin A treatment in patients with rheumatoid
arthritis. Cyclosporin A (CyA) and azathioprine (Aza) were compared
with respect to renal side effects in an open controlled, randomized
study of patients with rheumatoid arthritis. Twelve patients were
treated with CyA (mean dose 7.8 1.2 mg/kg/day) and 12 with
azathioprine for 26 weeks. All patients also received prednisolone 5
mg/day. The patients had normal serum creatinine (<120 jsmoles/liter)
and protein—free urine before the trial. CyA increased serum creatinine
in nine out of the II patients followed for 26 weeks, the mean increase
was approximately 50%. Creatinine clearance was reduced by 31%.
Mean arterial pressure (MAP) and serum potassium were significantly
increased by CyA. Urinary beta2-microglobulin excretion was signifi-
cantly increased by CyA, in five of the patients more than ten times.
Urinary kallikrein excretion was reduced by more than 50% and urinary
albumin excretion was doubled. All these parameters remained normal
and unchanged in the azathioprine group. CyA was withdrawn in seven
patients after 26 weeks. Urinary beta,-microglobulin was still increased
by 85% nine months after CyA treatment. The other parameters were
gradually normalized after three to nine months except for one patient
who developed renal failure. Urinary beta2-microglobulin excretion was
a very sensitive parameter for renal tubular damage in this study.
Cyclosporin (CyA) is a potent immunosuppressive drug
which has greatly improved the survival rate in organ transplan-
tation. It also may be nephrotoxic when used in recommended
doses [I], and serum creatinine is increased in the majority of
patients with renal allografts treated with CyA [2—4]. Examina-
tion of biopsies from transplanted kidneys has suggested that
CyA may cause interstitial fibrosis and tubular atrophy during
long—term treatment 5]. Little is known of the magnitude and
extent of the CyA nephrotoxicity on potential normal kidneys,
as most data comes from recipients of renal allografts or from
patients with compromised renal function when transplanted
with other organs.
CyA has been successfully used in the treatment of various
autoimmune diseases, and renal toxicity (raised serum creati-
nine and serum urea) was noted in 30% of patients treated for
more than one month with CyA for ocular inflammatory dis-
eases [6]. CyA increased urinary beta2-microglobulin excretion
in a patient with relapsing polychondritis, indicating a renal
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tubular damage [7]. The possible reversibility of these renal side
effects has been a matter of controversy.
In this paper we present the renal side effects of CyA given
for 26 weeks in patients with rheumatoid arthritis. We have
investigated different parameters of renal glomerular and tubu-
lar functions, and the effects on blood pressure and the
renin—angiotensin—aldosterone system. The aims of the study
were twofold: to investigate the effects of CyA in patients with
apparent normal kidney function and, secondly, to determine
reversibility and time needed to achieve pre-treatment values
for kidney function.
Methods
Patients
Twenty—four patients with rheumatoid arthritis, functional
stage I to 111 were studied. Twelve patients were treated with
CyA and 12 with azathioprine for 26 weeks in an open con-
trolled, randomized study design. Patients with proteinuria (I +
or greater with Boehringer BM-5 dipstick) or serum creatinine
greater than 120 imole/liter, with systemic blood pressure
exceeding 150/95 mm Hg, with impaired liver function, malig-
nancies and other serious concomitant diseases were excluded
from the study. The patients included had not received other
nefrotoxic drugs for their arthritis except for nonsteroid anti-
inflammatory drugs (NSAIDs) during the last three months
before the study.
One patient treated with CyA was withdrawn from the study
after three weeks because of increasing angina pectoris, and in
four patients the azathioprine treatment was discontinued after
one to five weeks because of liver toxicity or allergic
exanthema. One patient had to discontinue CyA treatment after
18 weeks because of gastrointestinal side effects, and one
patient stopped azathioprine treatment after 16 weeks because
of an unacceptable increase in disease activity. These patients
were, however, both included in the study and the last function
tests before drug discontinuation were used for the statistical
evaluation after 18 and 26 weeks of treatment. Thus, the study
includes II patients (seven females, median age 51 years, range
34 to 68 years) treated with CyA and eight patients (five
females, median age 58 years, range 42 to 73 years) treated with
azathioprine. Mean duration of the disease ws 6.5 4.1 years
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Table 1. Individual renal function tests for the cyclosporine treated patients before (C-O), after 26 weeks of treatment (N = Il), and nine
months after treatment (C-Il) (N = 7)
Pat
S-creatinine
jsmoleslliter
C-O 26 C-Il
S-beta2-microg
pg/liter
lobulin C-creatinine
mliter/min
C-O 26 C-Il
U-bet
C-O
a2-microgl
p.g124 hr
26
obulin
C-Il
U-kallikrein
units/24 hr
C-O 26 C-Il C-O
U-albumin
/sg/min
26 C-IlC-O 26 C-lI
AB 58 133 71 2625 7140 2625 128 60 101 138 3900 234 1.18 0.65 0.84 3.7 12.0 2.0
AS 53 88 53 2625 3780 2205 116 61 107 56 1125 181 1.03 0.23 1.06 3.4 5.1 3.9
OT lii 292 380 4725 13200 21000 49 22 10 464 16525 1200 0 0.05 0.09 16.0 44.4 7.4
RH 58 71 71 1575 1470 1575 96 115 156 67 172 80 0.04 0 0.16 2.2 3.1 3.1
AP 80 133 88 2365 2730 2295 50 39 47 200 6800 676 0.50 0.15 0.64 5.2 11.8 11.9
MAJ 53 80 71 2260 1260 1890 89 86 96 45 308 100 2.14 0.85 1.56 5.1 86.1 3.3
ES 62 53 7! 2195 905 1385 106 100 122 98 179 147 0.67 0.33 1.04 2.9 4.7 5.0
TL 80 80 1575 1900 174 163 62 41 0.96 0.30 5.4 4.9
BH 84 203 2835 3780 79 42 70 97 0.03 0.21 3.7 11.7
JS 97 124 4935 3360 50 51 46 464 0.36 0.28 2.6 4.6
TH 58 80 3150 1680 84 71 86 185 0.44 0.21 19.4 7.9
(range 1 to 17) in the CyA group and 8.8
18) in the azathioprine group.
Study design
6.0 years (range I to
Patients in the CyA group started with 10 mg/kg/day and the
mean dose was gradually reduced to 6.4 1.7 mg/kg/day at the
end of the study according to blood levels. Dosage reduction
was made according to the study protocol when serum creati-
nine increased above 130 tmoles/liter or when whole blood
CyA levels exceeded 1000 tg/liter during the first month and
800 sg/liter later. Mean dose for the whole treatment period was
7.8 1.2 mg/kg/day. The other group of patients received Aza
2.5 to 3.0 mg/kg/day throughout the study. All patients received
prednisolone 5 mg/day at the onset of the study, and the mean
prednisolone dose was gradually reduced to 2.9 1.1 mg/day in
the CyA group and to 4.7 1.7 mg/day in the azathioprine
group according to clinical effect.
All patients in both treatment groups were kept on a stable
dose of NSAIDs for at least one month before the trial. In the
CyA group the dose of NSAIDs was unchanged in six, with-
drawn in two (OT, AP, Table 1), reduced in two (MAJ, TH) and
increased in one patient (TL) during the study. There were only
minor adjustments of the NSAIDs dosage in the Aza group.
Blood pressure, blood samples, morning urine and pooled 24
hr urine were obtained twice during the control week and the
means of the two results were used as the control value (C-O).
During the 26 week treatment period, blood pressure, plasma
renin activity (PRA), and plasma aldosterone were controlled at
weeks ten and 26. The blood pressure was expressed as mean
arterial blood pressure (MAP = Diastolic blood pressure + 1/3
pulse pressure). Creatinine, beta2-microglobulin, sodium and
potassium in serum and CyA in whole blood were determined
weekly during the first ten weeks and then every second week
during the last 16 weeks of study. Pooled 24 hr urine and
morning urine were sampled during weeks 2, 6, 10, 18, and 26.
Pooled 24 hr urine samples were assayed for beta2-microglob-
ulin, albumin, kallikrein, sodium, potassium and creatinine.
N-acetyl-beta-glucosaminidase (NAG) was determined in morn-
ing urine.
All urine samples were stored without delay at + 4°C without
preservatives. When 24 hr urine collection was completed, the
urine was stored at —20°C for six months. This storage did not
affect the parameters investigated. Urine aliquots were ana-
lyzed immediately after thawing.
CyA treatment was continued for more than the protocolled
26 weeks in four patients for various reasons, these patients
were only followed the first six months in this study. In seven
patients CyA was withdrawn after 26 weeks; these patients
were then controlled at different time intervals during the first
six months (average three months) (mean of these observations
= CI) and then after six to 12 months (average nine months =
CII) after CyA withdrawal.
Biochemical analysis
Cyclosporin A was determined in whole blood using the
radioimmunoassay (RIA) kit provided by Sandoz Ltd. (Basle,
Switzerland) [81. The samples were taken in the morning as
trough values, approximately 12 hr after the last dose. Blood
was drawn into heparinized vacuum tubes and kept at room
temperature before analysis. The detection limit was 60 g!liter,
however the precision decreases substantially at levels below
200 tg/1iter. At a concentration of 200 sg/liter the coefficient of
variation between assay was 12% (N = 60), at 128 sg/liter 26%
(N = 40).
Urinary albumin was determined by the method described by
Ken and Chlouverakis [9] with the following modifications:
commercial rabbit anti-human albumin was obtained from
Dakopatts A/S, Denmark. '25J albumin was diluted with unla-
belled albumin to a final concentration between 0.3 and 0.5
mg!l00 mliter. The standard curve was constructed using albu-
min concentrations ranging between 0 to 16 mg/100 mliter.
Purified human albumin was purchased from Boehringer Mann-
heim (FRG). The complex between albumin antiserum and
albumin was precipitated using a 12.5%PEG 6000 solution in a
phosphate buffer. The mean albumin excretion in controls was
4,0 sg/min (upper limit 10.0 g/min) and the within assay
coefficient of variation was 9%.
Beta2-microglobulin in serum and urine was performed by
means of the Phadepas® beta2-microtest RIA-kit (Pharmacia
AB, Uppsala, Sweden). Urine was stored at pH > 6. The mean
serum concentration in controls was 2.2 0.15 mg/liter (upper
limit 4.0 mg/liter) and the within assay coefficient of variation
5%. The mean urinary excretion in controls was 90 g/24 hr
(upper limit 180 p.g/24 hr).
a P < 0.05, b P < 0.01.
100 (IS)
112 (20)
1.8 (3.7)
1.3 (1.2)
306 (212)
332 (300)
4.1 (0.5)
4.2 (0.7)
115 (15)b
100 (15)
1.3 (I.7Y'
1.5 (0.9)
261 (296)
279 (116)
4.2 (0.4)
4.3 (0.5)
115 (40)
105 (20)
1.8 (2.0)
1.8 (1.2)
266 (241)
274 (77)
4.6 (0•3)b
4.3 (0.2)
Urinary N-acetyl-beta-glucosaminidase (NAG) was deter-
mined according to the fluorometric method of Price and Dance
l0j. The assay was based on the release of 4-methylumbellif-
erone (MU) from methylumbelliferylglucosaminidine substrate.
One unit of enzyme activity is that which releases one nmole of
MU per hour at 37°C at pH 4.5. The activity was expressed as
units/cmoles creatinine. The mean values and standard devia-
tion in normal controls were 5.6 0.5 units/.cmoles creatinine.
The within assay coefficient of variation was 3%.
Urinary kallikrein was measured spectrophotometrically us-
ing the tripeptide 1-I-D-Val-Leu-Arg-pNA (AB Kabi, MOIndal,
Sweden) [II]. The amidolytic liberation of para-nitro-aniline
was measured at 405 nm against a sample blank where apronitin
was added to correct for other proteolytic enzymes. The
activity was given as units/24 hr. The mean values in normals
were 0.68 0.09 units/24 hr, and the within assay coefficient of
variation was 7%.
Plasma renin activity (PRA) was measured in ambulatory
patients in EDTA plasma with the angiotensin I—Squibb Radio—
immunoassay kit (Squibb Inc., Princeton, New Jersey, USA).
The results are expressed as the amount of angiotensin I
generated from plasma per time unit. The reference values in
our laboratory for ambulatory controls are 0 to 4 nmole/liter/hr,
and the within assay coefficient of variation 8%.
Aldosterone was estimated by a commercial radio-
immunoassay kit (Diagnostic Products Corp., USA), Normal
levels for ambulatory controls were 100 to 900 pmoie/liter and
the within assay coefficient of variation was 5%.
Statistical analysis
The results were expressed by their median values and
interquartile ranges (Q to Qi) unless otherwise stated. The
difference between the values obtained on week 2, 10, 18, and
26 were compared with the control period (C-O) for both
treatment groups, and non-parametric methods (paired
Wilcoxon test) were used to test the differences. We also
calculated the statistical differences between the control period
(C-O) and the post-treatment values three months (C-I) and nine
months (C-Il) after drug withdrawal for the seven patients who
discontinued CyA therapy after 26 weeks. A P value of less than
0.05 was considered significant. All calculations were made at
Department of Informatics, University of Oslo, Norway.
Results
Clinical effects on rheumatic disease
Both groups of patients improved in most objective clinical
arthritis parameters investigated, the results being somewhat
better in the CyA group. These results will be published
elsewhere [12] as this report only deals with the renal side
effects observed. The four patients with the highest serum
creatinine levels at week 26 were all in the group with the best
clinical effects of CyA.
Effects on MAP, PRA, aldosterone and potassium (Table 2)
MAP was significantly increased by CyA after ten weeks.
MAP increased in ten patients and to pathological values (MAP
> 120 mm Hg) in five of them. There was no correlation
between the increase in MAP and changes in the renal function
parameters. The patient with the most pronounced increase in
MAP had normal renal tubular and glomerular function during
the whole treatment period.
PRA was significantly reduced after ten weeks in the CyA
group, but was normalized after 26 weeks. Serum potassium
was increased by 0.5 mmole/liter after 26 weeks of CyA
treatment (P < 0.01). Serum potassium started to increase after
two weeks in four patients and was increased in ten patients
after 26 weeks, only in two patients to values higher than 5
mmoles/liter during the study. Urinary potassium excretion,
urinary NaJK ratio and serum aldosterone were unchanged by
CyA. Serum chloride increased from 106 to 108 mmoles/liter
(NS) after 26 weeks of CyA treatment.
There were no changes in any of thes parameters in the
azathioprine—treated patients.
Whole blood CyA concentration
After 2 weeks of treatment median CyA concentration was
410 g/liter (interquartile range 260 Lg/liter), after ten weeks
530 (350) .cg/liter, after 18 weeks 395 (370) rig/liter and after 26
weeks 410 (465) pg/liter.
Effects on creatinine clearance, serum creatinine and
heta2-microglobulin (Tables I and 3)
CyA increased serum creatinine by approximately 50%, this
increase being most significant (P < 0.005) after ten and 18
weeks. Serum creatinine was increased in nine patients, and to
pathological values (>120 moles/liter) in five. Creatinine was
unchanged during azathioprine treatment.
MAP, mm Hg
PRA, nmolesl!iter/hr
Aldosterone, pmoleslliier
S-potassium, ,nmolesl/iter
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Table 2. Effects of cyclosporin (CyA) or azathioprine (Aza) on mean arterial blood pressure (MAP), plasma renin activity (PRA), aldosterone
and potassium after 10 and 26 weeks of treatment, compared with pretreatment values (C-O) (median values and interquartile range)
Parameters C-O 10 26
Cya
Aza
Cya
Aza
Cya
Aza
Cya
Aza
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Table 3. Effects of treatment with cyclosporin (CyA) or azathioprine (Aza) on some renal glomerular function tests compared with
pretreatment period (C-O) (median values and interquartile range)
Parameters C-O 2 10 18 26
S-creatinine, pinoles/liter Cya
Aza
62 (28)
67 (29)
80 (44)
62 (35)
97 (70)C
67 (36) 97 (61)C62 (18) 88 (53)b71 (26)
S-beta2-microglobulin, pg/liter Cya
Aza
2625 (995)
2545 (445)
2730 (1910)
2675 (1880)
3150 (5795)
2055 (650)
2940 (2310)
1720 (735)
2730 (2310)
1805 (590)
Creatinine clearance, muter/mm Cya
Aza
89 (66)
94 (82)
86 (30)
100 (75) 67 (79)84 (80) 72 (39)81 (36) 61 (64)b107 (76)
a p < 0.05, b P < 0.01, C p < 0.005.
Table 4. Effects of treatment with cyclosporin (CyA) or azathioprine (Aza) on urinary protein and enzyme excretion compared with
pretreatment period (C-O) (median values and interquartile range)
Parameters C-O 2 10 18 26
U-beta2-microglobulin, j.ig/24 hr CyA
Aza
70
67
(81)
(42)
95
71
(376)
(135)
744
76
(2675)
(51)
174
42
(1667)
(51)
308
65
(953)"
(115)
U-albumin, Lg/min CyA
Aza
3.7
2.2
(2.5)
(26.7)
4.2
2.4
(2.8)
(23.6)
5.5
2.6
(7.7)
(9.6)
7.7
2.5
(6.8)a
(30.0)
7.9
2.2
(79)b
(17.0)
U-kallikrein, units/24 hr CyA 0.50 (0.97) 0.27 (0.57) 0.18 (0.26)a 0.27 (0.49)a 0.23 (0.20)"
i
U-NAG, ( . I
\pmoles creat:nine/
Aza
CyA
Aza
0.31
8.4
7.1
(0.53)
(5.5)
(5.5)
0.26
6.0
7.6
(0.40)
(2.7)
(12.0)
0.40
13.5
6.3
(0.55)
(22.2)
(5.0)
0.57
9.5
6.8
(0.78)
(10.2)
(5.7)
0.37
10.6
6.1
(0.41)
(8.1)
(6.1)
a P <0.05, b P <0.01.
than ten times in five of them (Fig. 1). The changes started after
two weeks of treatment and were significant from week ten.
Urinary albumin excretion increased in ten patients and was
doubled after 26 weeks of CyA treatment (P < 0.01). Only in
two patients was the albumin excretion higher than 15 j.g/min.
The albumin excretion tended to increase gradually with the
treatment time.
Urinary kallikrein excretion was very low during the control
period in three CyA-treated patients. In two of these patients
(OT, BH) CyA exerted the most pronounced effects on renal
function. In the eight other patients with normal control values
kallikrein excretion was reduced by more than 50% by CyA.
Urinary NAG excretion was unchanged by CyA.
Azathioprine treatment did not induce any alterations in the
ct ci urinary excretion of beta2-microglobulin, albumin, kallikrein or
NAG.
Predictive value of the kidney function parameters in the
control period (C-O)
In four of the CyA-treated patients (AB, OT, AP and BH)
most of the renal function parameters investigated were im-
paired by CyA (Table 1). In three of these patients (OT, AP,
BH), a combined analysis of creatinine clearance and the
urinary excretion of beta2-microglobulin and kallikrein during
the control period were of prognostic value. Serum creatinine
and serum beta2-microglobulin were less reliable as predictive
parameters for impaired renal function during CyA treatment.
In one of the four patients (AB) all control parameters were
normal.
In three other patients (AS, MAJ, JS) CyA induced selective
changes in urinary beta2-microglobulin excretion, in one of
them also in albumin excretion (MAJ). All control parameters
except creatinine clearance in one patient were normal in these
J
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C2 10 18 26
Time, weeks
Fig. 1. Urinary beta2-microglobulin excretion before (C), during( •), and after (•---•) CyA treatment. (±) mean SD.
Beta2-microglobulin in serum was increased 20% by CyA
after ten weeks (P < 0.05), but unchanged during the other
control weeks. There was a tendency (NS) towards a reduction
in beta2-microglobulin during azathioprine treatment.
Creatinine clearance was reduced by 31% after 26 weeks of
CyA treatment (P < 0.01). The clearance values were un-
changed by azathioprine.
Effects on urinary excretion of beta2-micro globulin, albumin,
kallikrein and NAG (Tables I and 4)
Beta2-microglobulin excretion was increased to pathological
values in eight of the CyA-treated patients and increased more
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S-beta2-m C-Creatinine
Fig. 2. Serum creatinine (p.moles/liter) serum heta2-microglobulin(sgIliter) and creatinine clearance (muter/mm) before , during , 3
months after 0 and 9 months after CyA treatment (median values
and interquartile ranges) (N = 7). (* P < 0.05 vs. C-O).
cases. In four patients (TL, RH, ES, TH) there were little or no
changes in the renal function and all control parameters were
normal in this group except for a low kallikrein excretion in one
patient (RH).
Effects of CyA withdrawal
The effects of CyA withdrawal were investigated in seven
patients (Table 1).
Serum creatinine nine months post-treatment was signifi-
cantly reduced from the mean values during CyA treatment, but
still 22% higher (P < 0.05) than before the treatment started. If
we exclude patient OT, there was no significant difference in
serum creatinine before and nine months after the trial. Creat-
mine clearance and serum beta2-microglobulin were normalized
in all but one patient (Fig. 2).
The urinary excretion of beta2-microglobulin, kallikrein and
albumin before, during and after treatment are shown in Fig. 3.
Urinary beta2-microglobulin excretion was still increased in all
patients nine months after treatment, in four patients to patho-
logical values. In two patients (OT, AP) the urinary excretion of
betamicroglobulin was more than 10,000 /Lg/24 hr three
months after the treatment was stopped (Fig. 1).
Urinary kallikrein excretion increased significantly after
treatment and was normalized after nine months, Urinary
albumin excretion was gradually normalized in all but two
patients. Serum potassium and MAP were normalized after nine
months.In one patient, renal function was gradually impaired
during CyA treatment and deteriorated further during the year
after drug discontinuation. This patient was a 68-year—old man
(OT) who suffered from rheumatoid arthritis the last 17 years.
Gold therapy initiated in 1968 was withdrawn after a few weeks
because of rash. The disease was then relatively inactive until
1983 and he never was treated with penicillamine or cytostatic
agents, nor with excessive amounts of NSAIDs. He was on a
small prednisolone dose before the trial. The last months before
the drug trial there was a general exacerbation of the rheuma-
toid arthritis. Apart from this disease he had been in good health
condition and never experienced symptoms of renal disease or
hypertension. During the trial he got CyA 1590 mg/kg (8.8
mg/kg/day) and the whole blood CyA levels were higher than
900 xg/liter during at least eight of the treatment weeks (Fig. 4).
The CyA treatment had an excellent effect on his rheumatoid
disease and treatment with acetylsalicylic acid was withdrawn
after two weeks of CyA treatment. Later he was not given
NSAIDs until after the last control, nine months after CyA
withdrawal. As can be seen from Table 1, all renal function
parameters deteriorated during the trial, and nine months after
drug withdrawal serum creatinine value was 380 mole/liter and
creatinine clearance 10 mliter/min.
A percutaneous renal biopsy was performed six months after
the CyA treatment was discontinued. On light microscopy (Fig.
5) 15 glomeruli were found, seven of them were sclerotic, the
others showed a moderate mesangial matrix increase, a mild
hypercellularity and a pericapsular fibrosis around some
glomeruli. The most pronounced pathological findings were in
the tubulointerstitial area. There were focal areas of a moderate
severe interstitial fibrosis and an interstitial inflammation. Atro-
120
100
80
60
40
20
3000
2000
1000
S-Creatinine
-f
120
100
80
60
40
20
1200
1000
800
600
400
200
6800 14180
U-beta2-m
1.20
1.00
0.80
0.60
0.40
L
12
10
8
6
4
2
44.8 39.2
U-albumin
0.20 I-
ow
U-kallikrein
Fig. 3. Urinary excretion of beta2-microglobulin (aug/24 hr), kallikrein(pg/liter), and albumin (g/min) before , during , 3 months after 0
and 9 months after CyA treatment, * P < 0.05 vs. C-O.
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Fig. 4. Serum creauinine (•—•) (p,mole/liter) and whole blood CyA
levels (O—O) (pg/liter) in the one patient (OT) with the most
impaired renal function. Symbols are: (•—•) cyclosporin +,
(•----•) cyclosporin —
C2 6 10 14 18 22 26 32 44 52 78
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Fig. S. Light micrograph of renal biopsy from patient OT showing severe tubular atrophy, interstitial fibrosis and focal interstitial inflammation.
(HE x 30).
phic tubules were seen in the fibrotic area. The vessels (small
arteries and arterioles) were moderately sclerotic without
thrombi. There were no amyloid deposits. Electron microscopy
confirmed the findings on light microscopy. Immunofluores-
cence microscopy showed variable and weak granular glomer-
ular deposits of IgG and C3.
Discussion
In the present study of eleven patients with rheumatoid
arthritis and presumptive normal renal function, CyA increased
MAP by 15%. The blood pressure increased to pathological
values in five of the patients and the increase in MAP was not
related to renal dysfunction. The effect on blood pressure in this
study is of the same order as in renal [2, 14] and heart [13]
transplanted patients and in patients with autoimmune diseases
[6].
Serum potassium increased in all patients but never exceeded
5.5 mmoles/liter. A moderate increase in serum potassium has
also been demonstrated in CyA -treated renal allografted pa-
tients [3, 15]. This increase has either been attributed to low
PRA, a reduced renal tubular sensitivity for aldosterone or to a
type IV hyperchioremic renal tubular acidosis [14, 15]. The
increased potassium values found in our study cannot be
explained by the reduction in GFR. PRA was significantly
reduced after ten weeks, but normalized after 26 weeks when
the serum potassium values were highest. An adjustment of the
NSAIDs dosage in three patients between weeks 10 to 26 could
have contributed to normalization of PRA at week 26. Serum
aldosterone values were unchanged. Serum chloride increased
2.0 mmoles/liter (NS) after 26 weeks, and as we did not
investigate either acid/base balance or urinary pH, we cannot
exclude a mild degree of hyperkalemic renal tubular acidosis.
Serum creatinine increased 50% during CyA treatment which
is of the same order as in CyA-treated renal transplanted
patients [2—4]. The increase could be seen after two weeks in
some cases but was not significant before ten weeks. Creatinine
clearance decreased by 31% with CyA, and as inulin clearance
also was reduced in parallel with creatinine clearance in CyA-
treated patients [13], this finding reflects a real reduction in
GFR by CyA.
Until now there are few available reports on the effects of
CyA on renal function in autoimmune diseases, but comparable
doses of CyA as in this study have been demonstrated to
increase serum creatinine by 50% in ocular inflammatory dis-
orders [6]. The increase was most pronounced in a patient on
concomitant naproxen therapy [6]. Combined therapy with
CyA and NSAIDs may therefore be especially harmful in some
cases. A possible contributing role of NSAIDs on the renal side
effects of CyA should also be taken into consideration in this
study. The NSAIDs were withdrawn after two weeks in one
patient (OT) and after ten weeks in one (AP) because of
excellent clinical effects of CyA. In both cases serum creatinine
and urinary beta2-microglobulin continued to rise throughout
the study. Minor adjustments of the NSAIDs dosage in three
patients were without detectable effects on renal function. As
the renal function parameters were normal in all but one patient
on stable doses of NSAIDs when the study started, and were
unaltered on relatively higher doses during Aza-treatment, it is
unlikely that NSAIDs per se were responsible for the renal side
effects. This does, however, not exclude an additional effect of
NSAIDs on the CyA nefrotoxicity in this study.
Urinary beta2-microglobulin was the most sensitive parame-
ter for CyA toxicity in this study and was increased more than
ten times in five patients. Excretion of urinary beta2-microglob-
ulin has been considered a valuable marker of renal interstitial
disease both in patients with rheumatoid arthritis [16] and with
analgesic nephropathy [17], two conditions where the excretion
of this microprotein often is very high in spite of normal serum
creatinine values. Urinary beta2-microglobulin excretion has
also been reported to increase in patients with autoimmune
diseases treated with CyA [7]. Increased serum beta2-microglob-
ulin above the renal threshold value could be considered an
attributative factor to elevated urine excretion in only two
patients in this study. In the other patients serum beta2-
microglobulin was within normal limits.
The urinary excretion of NAG has also been considered a
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sensitive parameter of renal damage in this area. increased
values hve been reported in various kidney disorders [18, 191
and in experimental CyA toxicity in rats [201. In our study
urinary NAG excretion was unchanged and independent of the
other renal function parameters, and was of no value as a
parameter of CyA toxicity.
Reduced urinary kallikrein excretion has been reported in
cases of hypertension [21], glomerulonephritis [22], sulphinpyr-
azone nephrotoxicity [23] and in renal transplant rejection [24].
A correlation between kailikrein excretion and renal blood flow
has been suggested [21], and the low kallikrein excretion found
after CyA in our study could thus indicate a reduced renal blood
flow. The method used in this study is specific, but rather
insensitive, and we have found very low values in patients with
impaired renal function [25]. However, this enzyme was of
value as a predictive parameter for CyA toxicity.
How reversible are the CyA-induced changes of renal func-
tion? Most data on CyA withdrawal comes from renal trans-
planted patients. In one such study [27] serum creatinine fell to
the level of the control group within 14 days after conversion to
Aza of patients treated with CyA for three months. Data on
CyA withdrawal in autoimmune diseases are few, but in an
interim report on 349 patients with autoimmune diseases treated
with CyA [26] effects of CyA withdrawal are reported in 137
cases. Renal function seemed to normalize within two months
with a possible exception for patients older than 50 years and
patients with rheumatoid arthritis.
in our study CyA was withdrawn in seven patients; in six of
them the different renal function parameters gradually normal-
ized with the exception of beta2-microglobulin. Creatinine
clearance was normalized after three months, and serum creat-
mine after nine months.
Urinary beta2-microglobulin was still increased in all cases
nine months after treatment and was pathological in four
patients. It seemed that glomerular function normalized earlier
than tubular function in CyA-treated patients, and urinary
beta2-microglobulin was therefore a valuable control parameter
for renal function during and after CyA treatment in patients
with autoimmune diseases.
One case (0.1.) progressed to renal failure during and after
CyA treatment. Retrospectively, we know from the laboratory
parameters that his renal glomerular and tubular function was
reduced before the study. The renal biopsy findings in this case
are consistent with renal biopsy findings seen after more than
one year of CyA treatment in renal transplanted patients [5], but
the histological findings are, however, not conclusive. Similar
findings have also been demonstrated in patients with chronic
rheumatoid arthritis and normal serum creatinine both with [28]
and without [29] high consumption of NSAIDs or analgesics.
We cannot therefore exclude that the histological findings in our
patient were present before the study. The patient was, how-
ever, not on other nephrotoxic drugs, apart from small doses of
salicylates during the first two weeks, and had no other obvious
reason for a rapid progression into renal failure. His serum
creatinine values also fluctuated in parallel with the whole blood
CyA concentrations. It is therefore reasonable to conclude that
CyA at least accelerated the renal damage in this case.
Lastly, we started this trial with CyA 10 mg/kg/day and
reduced the dose to 6.4 mg/kg/day within 26 weeks, a dose
which is now considered high also in renal transplanted pa-
tients, This dose was, however, an acceptable dose at the time
of this study [6, 26]. In patients with immunologically mediated
diseases such as rheumatoid arthritis, it is even more important
to avoid nephrotoxicity. We therefore have to consider the
therapeutic window of CyA in each case, and to reduce the CyA
to the lowest possible dose. We have now started a new trial in
patients with rheumatoid arthritis where the initial CyA dose of
5 mg/kg will be adjusted during the study to achieve whole
blood levels of 200 to 500 g/liter.
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